BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12509713)

  • 1. Cessation of enzyme replacement therapy in Gaucher disease.
    Grinzaid KA; Geller E; Hanna SL; Elsas LJ
    Genet Med; 2002; 4(6):427-33. PubMed ID: 12509713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.
    El-Beshlawy A; Ragab L; Youssry I; Yakout K; El-Kiki H; Eid K; Mansour IM; Abd El-Hamid S; Yang M; Mistry PK
    J Inherit Metab Dis; 2006 Feb; 29(1):92-8. PubMed ID: 16601874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J; Szücs FZ; Benkö K; Maródi L
    Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling changes in biomarkers in Gaucher disease patients receiving enzyme replacement therapy using a pathophysiological model.
    Vigan M; Stirnemann J; Caillaud C; Froissart R; Boutten A; Fantin B; Belmatoug N; Mentré F
    Orphanet J Rare Dis; 2014 Jun; 9():95. PubMed ID: 24980507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A; Tylki-Szymanska A; Vellodi A; Belmatoug N; Grabowski GA; Kolodny EH; Batista JL; Cox GF; Mistry PK
    Mol Genet Metab; 2017; 120(1-2):47-56. PubMed ID: 28040394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics.
    Giraldo P; Pocoví M; Pérez-Calvo J; Rubio-Félix D; Giralt M
    Haematologica; 2000 Aug; 85(8):792-9. PubMed ID: 10942924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM
    Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical-genetic characteristics and treatment outcomes of Turkish children with Gaucher disease type 1 and type 3: A sixteen year single-center experience.
    Gumus E; Karhan AN; Hizarcioglu-Gulsen H; Demir H; Ozen H; Saltik Temizel IN; Dokmeci Emre S; Yuce A
    Eur J Med Genet; 2021 Nov; 64(11):104339. PubMed ID: 34500086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
    Lebel E; Elstein D; Peleg A; Reinus C; Zimran A; Amir G
    Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy for Gaucher disease in Australia.
    Goldblatt J; Szer J; Fletcher JM; McGill J; Rowell JA; Wilson M
    Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
    J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
    Grigorescu-Sido P; Drugan C; Alkhzouz C; Zimmermann A; Coldea C; Denes C; Grigorescu MD; Cret V; Bucerzan S
    Eur J Intern Med; 2010 Apr; 21(2):104-13. PubMed ID: 20206881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
    Sechi A; Deroma L; Dardis A; Ciana G; Bertin N; Concolino D; Linari S; Perria C; Bembi B
    Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy.
    Schiffmann R; Mankin H; Dambrosia JM; Xavier RJ; Kreps C; Hill SC; Barton NW; Rosenthal DI
    Blood Cells Mol Dis; 2002; 28(2):288-96. PubMed ID: 12064924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gaucher disease among Chinese patients: review on genotype/phenotype correlation from 29 patients and identification of novel and rare alleles.
    Choy FY; Zhang W; Shi HP; Zay A; Campbell T; Tang N; Ferreira P
    Blood Cells Mol Dis; 2007; 38(3):287-93. PubMed ID: 17196853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease.
    Andrade-Campos M; Alfonso P; Irun P; Armstrong J; Calvo C; Dalmau J; Domingo MR; Barbera JL; Cano H; Fernandez-Galán MA; Franco R; Gracia I; Gracia-Antequera M; Ibañez A; Lendinez F; Madruga M; Martin-Hernández E; O'Callaghan MDM; Del Soto AP; Del Prado YR; Sancho-Val I; Sanjurjo P; Pocovi M; Giraldo P
    Orphanet J Rare Dis; 2017 May; 12(1):84. PubMed ID: 28468677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
    Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources.
    Grabowski GA; Barton NW; Pastores G; Dambrosia JM; Banerjee TK; McKee MA; Parker C; Schiffmann R; Hill SC; Brady RO
    Ann Intern Med; 1995 Jan; 122(1):33-9. PubMed ID: 7985893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gaucher disease: studies of phenotype, molecular diagnosis and treatment.
    Rice EO; Mifflin TE; Sakallah S; Lee RE; Sansieri CA; Barranger JA
    Clin Genet; 1996 Mar; 49(3):111-8. PubMed ID: 8737974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.